Sullivan Timothy Eugene's Form 4 filing
Apellis Pharmaceuticals, Inc.APLS · filed Dec 1, 2023
- Accession no.
- 0001127602-23-028592
- Filed
- Dec 1, 2023
- Trade date
- Nov 30, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $774.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sullivan Timothy EugeneCIK 0001707000 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 30, 2023 | Common Stock | MOption exerciseAcquired | +14,158 | $10.03 | +$142,004.74 | 91,871 | Direct | |
| Nov 30, 2023 | Common Stock | SSaleDisposed | −13,858 | $54.73 | −$758,448.34 | 78,013 | Direct | |
| Nov 30, 2023 | Common Stock | SSaleDisposed | −300 | $54.79F3 | −$16,437 | 77,713 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 30, 2023 | Common Stock | MOption exerciseDisposed | −14,158 | $0.00 | $0 | 267,903 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $54.780 - $54.790. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.